95 related articles for article (PubMed ID: 16979236)
1. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice.
Vasconcelos FC; Cavalcanti GB; Silva KL; de Meis E; Kwee JK; Rumjanek VM; Maia RC
Leuk Res; 2007 Apr; 31(4):445-54. PubMed ID: 16979236
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976
[TBL] [Abstract][Full Text] [Related]
3. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
[TBL] [Abstract][Full Text] [Related]
4. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.
Vasconcelos FC; Silva KL; Souza PS; Silva LF; Moellmann-Coelho A; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2011 May; 80(3):158-66. PubMed ID: 21520403
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
Styczynski J; Wysocki M; Debski R; Czyzewski K; Kolodziej B; Rafinska B; Kubicka M; Koltan S; Koltan A; Pogorzala M; Kurylak A; Olszewska-Slonina D; Balwierz W; Juraszewska E; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Malinowska I; Stanczak E; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Maciejka-Kapuscinska L
J Cancer Res Clin Oncol; 2007 Nov; 133(11):875-93. PubMed ID: 17671794
[TBL] [Abstract][Full Text] [Related]
6. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
[TBL] [Abstract][Full Text] [Related]
7. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
Ascione A; Cianfriglia M; Dupuis ML; Mallano A; Sau A; Pellizzari Tregno F; Pezzola S; Caccuri AM
Cancer Chemother Pharmacol; 2009 Jul; 64(2):419-24. PubMed ID: 19288261
[TBL] [Abstract][Full Text] [Related]
8. MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation.
Park SH; Park CJ; Kim DY; Lee BR; Kim YJ; Cho YU; Jang S
Leuk Res; 2015 Oct; 39(10):1109-16. PubMed ID: 26248945
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of phenothiazines on MRP1 and P-glycoprotein activity.
Wesołowska O; Molnar J; Ocsovszki I; Michalak K
In Vivo; 2009; 23(6):943-7. PubMed ID: 20023237
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
[TBL] [Abstract][Full Text] [Related]
11. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
Maia RC; Carriço MK; Klumb CE; Noronha H; Coelho AM; Vasconcelos FC; Ruimanek VM
J Exp Clin Cancer Res; 1997 Dec; 16(4):419-24. PubMed ID: 9505216
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.
Swerts K; de Moerloose B; Dhooge C; Noens L; Laureys G; Benoit Y; Philippé J
Leuk Lymphoma; 2004 Nov; 45(11):2221-8. PubMed ID: 15512810
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups.
Legrand O; Zompi S; Perrot JY; Faussat AM; Benderra Z; Chaoui D; Marie JP
Haematologica; 2004 Jan; 89(1):34-41. PubMed ID: 14754604
[TBL] [Abstract][Full Text] [Related]
15. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM
Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050
[TBL] [Abstract][Full Text] [Related]
16. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
Broxterman HJ; Sonneveld P; Feller N; Ossenkoppele GJ; Währer DC; Eekman CA; Schoester M; Lankelma J; Pinedo HM; Löwenberg B; Schuurhuis GJ
Blood; 1996 Jun; 87(11):4809-16. PubMed ID: 8639853
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia.
Fujimaki S; Funato T; Harigae H; Fujiwara J; Kameoka J; Meguro K; Kaku M; Sasaki T
Clin Chem; 2002 Jun; 48(6 Pt 1):811-7. PubMed ID: 12028995
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines.
Dogan AL; Legrand O; Faussat AM; Perrot JY; Marie JP
Leuk Res; 2004 Jun; 28(6):619-22. PubMed ID: 15120939
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: Biological and prognosis implications.
da Silveira Júnior LS; Soares VL; Jardim da Silva AS; Gil EA; Pereira de Araújo MDG; Merces Gonçalves CA; Paiva AS; Moura de Oliveira TM; Oliveira GHM; Kramer Cavacanti E Silva DG; de Araújo Moura Lemos TM; Moretti Rebecchi IM; de Farias Sales VS; Luchessi AD; Cavalcanti Júnior GB
Int J Lab Hematol; 2020 Oct; 42(5):594-603. PubMed ID: 32452631
[TBL] [Abstract][Full Text] [Related]
20. MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients.
Mahjoubi F; Akbari S; Montazeri M; Moshyri F
Genet Mol Res; 2008; 7(4):1369-74. PubMed ID: 19065772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
